{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:32:54Z","timestamp":1773077574971,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T00:00:00Z","timestamp":1337040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10384-012-0139-2","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T00:14:22Z","timestamp":1336954462000},"page":"339-345","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of switching to travoprost\/timolol fixed-combination therapy from latanoprost monotherapy"],"prefix":"10.1007","volume":"56","author":[{"given":"Kenji","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,15]]},"reference":[{"key":"139_CR1","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1167\/iovs.07-0290","volume":"48","author":"DS Friedman","year":"2007","unstructured":"Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"139_CR2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archophthalmol.2010.345","volume":"129","author":"DT Quek","year":"2011","unstructured":"Quek DT, Ong GT, Perera SA, Lamoureux EL, Aung T. Persistence of patients receiving topical glaucoma monotherapy in an Asian population. Arch Ophthalmol. 2011;129:643\u20138.","journal-title":"Arch Ophthalmol"},{"key":"139_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874364101004010007","volume":"4","author":"K Kashiwagi","year":"2010","unstructured":"Kashiwagi K. Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community. Open Ophthalmol J. 2010;4:7\u201311.","journal-title":"Open Ophthalmol J"},{"key":"139_CR4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/IJG.0b013e31815c5f3f","volume":"17","author":"CA McCarty","year":"2008","unstructured":"McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, et al. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008;17:372\u20137.","journal-title":"J Glaucoma"},{"key":"139_CR5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"139_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","volume":"18","author":"F Djafari","year":"2009","unstructured":"Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238\u201343.","journal-title":"J Glaucoma"},{"key":"139_CR7","first-page":"459","volume":"4","author":"N Pfeiffer","year":"2010","unstructured":"Pfeiffer N, Scherzer ML, Maier H, Schoelzel S, Jasek MC, Stewart JA, et al. Safety and efficacy of changing to the travoprost\/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. Clin Ophthalmol. 2010;4:459\u201366.","journal-title":"Clin Ophthalmol"},{"key":"139_CR8","first-page":"411","volume":"49","author":"Z Mandic","year":"2010","unstructured":"Mandic Z, Novak-Laus K, Bojic L, Popovic-Suic S, Ekert M, Dosen VM, et al. Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004\u00a0%\/timolol 0.5\u00a0%) in 6\u00a0months follow up period. Acta Clin Croat. 2010;49:411\u20139.","journal-title":"Acta Clin Croat"},{"key":"139_CR9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14656566.2011.551007","volume":"12","author":"P Denis","year":"2011","unstructured":"Denis P. Travoprost\/timolol fixed combination in the management of open-angle glaucoma: a clinical review. Expert Opin Pharmacother. 2011;12:463\u201371.","journal-title":"Expert Opin Pharmacother"},{"key":"139_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1358\/dot.2007.43.2.1032058","volume":"43","author":"RJ Noecker","year":"2007","unstructured":"Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004\u00a0%\/timolol 0.5\u00a0% fixed combination. Drugs Today (Barc). 2007;43:77\u201383.","journal-title":"Drugs Today (Barc)"},{"key":"139_CR11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656566.9.6.1059","volume":"9","author":"M Herceg","year":"2008","unstructured":"Herceg M, Noecker R. Travoprost\/timolol fixed combination. Expert Opin Pharmacother. 2008;9:1059\u201365.","journal-title":"Expert Opin Pharmacother"},{"key":"139_CR12","doi-asserted-by":"crossref","unstructured":"Hoy SM, Keam SJ , Keating GM. Travoprost\/timolol. Drugs Aging. 2006;23:587\u201397 (discussion 98\u20139).","DOI":"10.2165\/00002512-200623070-00005"},{"key":"139_CR13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1185\/03007995.2011.613923","volume":"27","author":"F Aptel","year":"2011","unstructured":"Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27:1949\u201358.","journal-title":"Curr Med Res Opin"},{"key":"139_CR14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10384-010-0855-4","volume":"54","author":"SW Cho","year":"2010","unstructured":"Cho SW, Kim JM, Park KH, Choi CY. Effects of brimonidine 0.2\u00a0%\u2013timolol 0.5\u00a0% fixed-combination therapy for glaucoma. Jpn J Ophthalmol. 2010;54:407\u201313.","journal-title":"Jpn J Ophthalmol"},{"key":"139_CR15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.121.11.1537","volume":"121","author":"K Miyata","year":"2003","unstructured":"Miyata K, Amano S, Sawa M, Nishida T. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol. 2003;121:1537\u20139.","journal-title":"Arch Ophthalmol"},{"key":"139_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2005.02.043","volume":"140","author":"HS Barnebey","year":"2005","unstructured":"Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, et al. The safety and efficacy of travoprost 0.004\u00a0%\/timolol 0.5\u00a0% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1\u20137.","journal-title":"Am J Ophthalmol"},{"key":"139_CR17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(02)01010-2","volume":"109","author":"RL Fellman","year":"2002","unstructured":"Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, et al. Comparison of travoprost 0.0015\u00a0% and 0.004\u00a0% with timolol 0.5\u00a0% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109:998\u20131008.","journal-title":"Ophthalmology"},{"key":"139_CR18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00061198-200110000-00010","volume":"10","author":"I Goldberg","year":"2001","unstructured":"Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK. Comparison of topical travoprost eye drops given once daily and timolol 0.5\u00a0% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414\u201322.","journal-title":"J Glaucoma"},{"key":"139_CR19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","volume":"132","author":"PA Netland","year":"2001","unstructured":"Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472\u201384.","journal-title":"Am J Ophthalmol"},{"key":"139_CR20","first-page":"1806","volume":"17","author":"DA Ammar","year":"2011","unstructured":"Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806\u201313.","journal-title":"Mol Vis"},{"key":"139_CR21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"DA Ammar","year":"2010","unstructured":"Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837\u201345.","journal-title":"Adv Ther"},{"key":"139_CR22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/eye.2011.134","volume":"25","author":"Y Kitazawa","year":"2011","unstructured":"Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y. Travoprost 0.004\u00a0%\/timolol 0.5\u00a0%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond). 2011;25:1161\u20139.","journal-title":"Eye (Lond)"},{"key":"139_CR23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10384-011-0078-3","volume":"55","author":"HK Cho","year":"2011","unstructured":"Cho HK, Park MH, Moon JI. Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs. Jpn J Ophthalmol. 2011;55:670\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"139_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.eye.6701859","volume":"20","author":"C Tattersall","year":"2006","unstructured":"Tattersall C, Vernon S, Singh R. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage. Eye (Lond). 2006;20:221\u20135.","journal-title":"Eye (Lond)"},{"key":"139_CR25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/bjo.84.7.710","volume":"84","author":"A Waldock","year":"2000","unstructured":"Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710\u20133.","journal-title":"Br J Ophthalmol"},{"key":"139_CR26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2165\/00002512-199711050-00003","volume":"11","author":"JP Diamond","year":"1997","unstructured":"Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging. 1997;11:352\u201360.","journal-title":"Drugs Aging"},{"key":"139_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archopht.123.1.35","volume":"123","author":"SA Gandolfi","year":"2005","unstructured":"Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol. 2005;123:35\u20138.","journal-title":"Arch Ophthalmol"},{"key":"139_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7748\/ns2000.10.15.4.35.c2929","volume":"15","author":"JP Snape","year":"2000","unstructured":"Snape JP, Waldock A. Spirometry for patients prescribed topical beta-blockers. Nurs Stand. 2000;15:35\u20138.","journal-title":"Nurs Stand"},{"key":"139_CR29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajo.2004.04.022","volume":"138","author":"JH Liu","year":"2004","unstructured":"Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389\u201395.","journal-title":"Am J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-012-0139-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0139-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T17:08:42Z","timestamp":1561741722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-012-0139-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s10384-012-0139-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,15]]}}}